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Insulin-like growth factor-binding protein-3 and -5
(IGFBP-3 and -5) have been shown to bind insulin-like
growth factor-I and -II (IGF-I and -II) with high affinity.
Previous studies have proposed that the N-terminal re-
gion of IGFBP-5 contains a hydrophobic patch between
residues 49 and 74 that is required for high affinity
binding. These studies were undertaken to determine if
mutagenesis of several of these residues resulted in a
reduction of the affinity of IGFBP-3 and -5 for IGF-I.
Substitutions for residues 68, 69, 70, 73, and 74 in IG-
FBP-5 (changing one charged residue, Lys68, to a neutral
one and the four hydrophobic residues to nonhydropho-
bic residues) resulted in an ;1000-fold reduction in the
affinity of IGFBP-5 for IGF-I. Substitutions for homolo-
gous residues in IGFBP-3 also resulted in a >1000-fold
reduction in affinity. The physiologic consequence of
this reduction was that IGFBP-3 and -5 became very
weak inhibitors of IGF-I-stimulated cell migration and
DNA synthesis. Likewise, the ability of IGFBP-5 to in-
hibit IGF-I-stimulated receptor phosphorylation was at-
tenuated. These changes did not appear to be because of
alterations in protein folding induced by mutagenesis,
because the IGFBP-5 mutant was fully susceptible to
proteolytic cleavage by a specific IGFBP-5 protease. In
summary, residues 68, 69, 70, 73, and 74 in IGFBP-5 ap-
pear to be critical for high affinity binding to IGF-I.
Homologous residues in IGFBP-3 are also required, sug-
gesting that they form a similar binding pocket and that
for both proteins these residues form an important com-
ponent of the core binding site. The availability of these
mutants will make it possible to determine if there are
direct, non-IGF-I-dependent effects of IGFBP-3 and -5 on
cellular physiologic processes in cell types that secrete
IGF-I.
The insulin-like growth factor-binding proteins (IGFBPs)1
are known to have high affinity for IGF-I and -II, and in most
cases, the affinity of the intact proteins is greater than the
IGF-I receptor (1). Therefore, IGFBPs are capable of regulating
the equilibrium distribution of IGF-I and -II between that
bound to the receptor and that bound to the binding proteins in
solution or in extracellular matrix and on cell surfaces (2, 3).
Because IGFBPs generally exist in a molar excess over IGF-I in
extracellular fluids, they potentially control the amount of re-
ceptor stimulation that occurs under equilibrium conditions
(4). Several investigators have been interested in the domains
of the IGFBPs that mediate IGF-I and -II binding. In general,
this has been analyzed by determining the affinities of various
IGFBP fragments (5). Both N- and C-terminal fragments of
IGFBP-3 and -5 have been shown to have detectable binding
affinity for IGF-I and -II, although generally their affinities are
reduced between 100- and 1000-fold compared with the native
proteins (5–10). Affinities of the IGFBPs can also be modified
by post-translational modifications other than proteolysis, in-
cluding glycosylation and phosphorylation, but in general these
studies have not led to hypotheses regarding the location of the
IGF-I binding site (11–12). In addition, three-dimensional
structural analysis of IGF-I and -II has enabled investigators to
make predictions about the regions of IGFBPs that are likely to
interact with hydrophobic and charged regions within the IGFs
themselves (13–19).
The IGFBPs share a common domain organization. The
highest conservation is found in the N terminus of the protein
(i.e. the first 80 amino acids) in the C-terminal region. Twelve
conserved cysteines are found in the N-terminal domain and
six in the C-terminal domain. The central regions are much less
well conserved and do not contain cysteines, with the exception
of IGFBP-4.
It has been proposed, based on fragment analysis, that the
high affinity binding site for IGFs is located in the N-terminal
domain, although studies with IGFBP-2 and -3 have suggested
that C-terminal domain binding components are also present
(5, 20, 21). A recent study by Kalus et al. (6) using solution
NMR demonstrated that the N-terminal domain of IGFBP-5
contained one high affinity site for IGF-I and -II binding. These
investigators further determined that a hydrophobic patch
(residues 49, 50, 69, 73, and 74) and a critical charged residue,
lysine 68, existed within this motif that probably accounted for
the binding of this fragment. Because the study by Kalus et al.
(6) did not use the intact protein, these studies were conducted
to determine if altering these residues by in vitro mutagenesis
in the intact form of IGFBP-5 would result in reduced affinity
for IGF-I and therefore whether the model of the binding
pocket formulated using data obtained with the IGFBP-5 frag-
ment was also valid for the intact protein. We further tested
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the importance of these specific residues and the applicability
of the model by making homologous substitutions in IGFBP-3.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human IGF-I was a gift from Genentech
(South San Francisco, CA). Des 1–3 IGF-I was a gift from Monsanto,
Inc. (St. Louis, MO). Human dermal fibroblasts (GM-10A) were pur-
chased from Coriell Institute (Camden, NJ). Chinese hamster ovary K1
cells were obtained from the Lineberger Comprehensive Cancer Tissue
Culture Facility (Chapel Hill, NC). The mammalian expression vector
pcDNA 3.1 and TOPO TA cloning kit were obtained from Invitrogen
(Carlsbad, CA). Strataclean resin was purchased from Stratagene (La
Jolla, CA). The antisera that had been prepared using human IGFBP-3
and IGFBP-5 have been described previously (22). The antiphosphoty-
rosine antibody (PY99) and an antibody against the b subunit of the
IGF-I receptor (C-20) were obtained from Santa Cruz Biotechnology Co.
(Santa Cruz, CA).
Construction of Plasmids That Express Native and Mutant Forms of
IGFBPs—The preparation of expression vector pRcRSV-IGFBP-5 that
contains a full-length human IGFBP-5 cDNA has been described pre-
viously (23). Mutant IGFBP-5 cDNA was prepared in pRcRSV-IGFBP-5
as described previously (23). Single-stranded phagemid-DNA was gen-
erated from pRcRSV-IGFBP-5, and mutations were introduced using
synthetic oligonucleotides as substrates for antisense DNA synthesis.
The following complementary oligonucleotide was used to mutate Lys68,
Pro69, Leu70, Leu73, and Leu74 to Asn, Gln, Gln, Gln, and Gln: ccc gcg gcc
gtg ctg ctg ggc gtg ctg ctg att ctc ctc gtc ctg.
A human IGFBP-3 cDNA was cloned into pcDNA 3.1 vector
(pcDNA3-IGFBP-3) from pNUT-IGFBP-3 that contained a full-length
human IGFBP-3 cDNA (22). Arg69, Pro70, Leu71, Leu74, and Leu75 of
IGFBP-3 were mutated to Ser, Ala, Ser, Gln, and Gly using oligonu-
cleotides that contained the desired substitutions and restriction en-
zyme cleavage sites as primers for PCR. The 59-half of the IGFBP-3
sequence that included the start codon of IGFBP-3 to nucleotide 338
was amplified using a 59-primer that had the wild type sequence and a
39-primer that had the substituted sequence and an EcoRV site (primer
A). The 39-prime portion of the IGFBP-3 sequence that spans nucleotide
286 to the 39-end of IGFBP-3 was amplified using a 59-primer that
contained the mutated sequence and a Msc site and a 39-primer that
contained the wild type sequence (primer B). PCR was performed using
pcDNA3.1-IGFBP-3 as a template using an Advantage PCR kit (CLON-
TECH, Palo Alto, CA). The PCR products were then purified by adding
5 ml of Strataclean resin followed by centrifugation. The supernatant
was digested with EcoRV (59-fragment) or Msc (39-fragment) for 3 h at
37 °C. The digests were run on 2% agarose gel (NuSieve), and the bands
that corresponded to the expected molecular weights were excised,
frozen, and thawed. The material that was recovered from the thawed
gel was combined (59-fragment and 39-fragments) and ligated using T4
DNA ligase and then incubating at room temperature overnight. The
ligation mixture was then amplified by PCR using 59-primer A and
39-primer B to create the full-length IGFBP-3 with the mutated se-
quences. This PCR product was cloned into pcDNA 3.1 using a TOPO
TA cloning kit according to the manufacturer’s protocol. After selection,
the plasmids thus created were sequenced, and those containing the
correct sequences were amplified and purified as described previously
(24).
Preparation of Native IGFBP-3 and IGFBP-5 and the IGFBP Mu-
tants from Chinese Hamster Ovary Cells That Were Expressing These
IGFBPs—Chinese hamster ovary (K1) cells were transfected with
pRcRSV that contained cDNA from either native or mutant IGFBP-5,
pNUT-IGFBP-3 (22), or the pcDNA3.1 mutant IGFBP-3 using poly-L-
ornithine (25). Positive clones were selected with 800 mg/ml G418 as
described previously (23). The native forms of recombinant IGFBPs
were purified from the conditioned medium of the transfected Chinese
hamster ovary cells as described previously (3, 22). The mutant form of
IGFBP-5 was purified by phenyl-Sepharose and IGF-I affinity chroma-
tography (to remove IGFBP-4) as described previously (22). The mate-
rial that was excluded from the column was equilibrated with 50 mM
NaH2PO4, 2 mM EDTA, 0.1 M NaCl, pH 7.0, applied to an heparin-
Sepharose affinity column and eluted in the same buffer containing 1.0
M NaCl. This fraction was purified to homogeneity by reverse phase
HPLC as described previously (26). The IGFBP-3 mutant was purified
by phenyl-Sepharose as described (22), then equilibrated with 50 mM
NaH2PO4, 2 mM EDTA, 25 mM NaCl, applied to a heparin-Sepharose
column, and eluted in the same buffer containing 1.0 M NaCl. The
eluate was further purified by lectin affinity chromatography using
wheat germ agglutinin. The active fractions were eluted using 0.5 M
N-acetyl-D-glucosamine and purified further by HPLC (26). Purification
was monitored by immunoblotting using specific, high affinity IGFBP-3
and -5 antisera. Purity was proven by SDS-polyacrylamide gel electro-
phoresis with silver staining, and the amount of each protein was
determined.
125I-IGF-I Binding Assay—The affinity of native and mutant IGFBPs
for 125I-IGF-I was determined as described previously (19). Briefly,
20,000 cpm of 125I-IGF-I was incubated with 0–100 ng of native or
mutant IGFBPs in 0.25 ml of 0.1 M HEPES, 44 mM sodium phosphate,
0.1% Triton X-100, 0.1% BSA, 0.2% sodium azide, pH 6.0, for 1 h at
room temperature. Bound and free IGF-I were separated by precipita-
tion using 12% polyethylene glycol (Mr 8000–12,000). Scatchard anal-
ysis was also performed. Duplicate tubes were incubated with increas-
ing concentrations of IGF-I (0.053–1.33 M), and bound and free IGF-I
were separated by precipitation using 12% polyethylene glycol (Mr
8000–12,000) as described previously (27). The data were then ana-
lyzed according to the method of Scatchard, and the results that were
obtained with native IGFBP-3 or -5 were compared with those obtained
using the mutants.
Ligand Blotting—Ten or forty nanograms of IGFBPs were mixed
with Laemmli sample buffer in the absence of a reducing agent and
incubated at 65 °C for 10 min. The samples were then separated on a
12.5% SDS-polyacrylamide gel and transferred onto polyvinylidene di-
fluoride membrane as described previously (24). The membrane was
blocked with 10 mM Tris, 150 mM NaCl, 0.5 mg/ml sodium azide, pH 7.4,
plus 3% Nonidet P-40 for 15 min and then washed with this buffer
containing 1% BSA for 2 h, followed by this buffer plus 0.1% Tween 20
for 10 min at 4 °C. The membrane was then incubated with 100,000
cpm/ml 125I-IGF-I in this buffer (total volume 4 cc) containing 1% BSA
and 0.1% Tween 20 for 20 h at 4 °C. The membrane was then washed
three times with this buffer containing 0.1% Tween 20 and three times
with this buffer alone for 15 min, each with gentle agitation at 4 °C. The
membrane was dried and exposed to x-ray film (Kodak XAR) to visual-
ize the binding of 125I-IGF-I. The same membranes were rehydrated
with methanol and probed with antisera against human IGFBP-3 or
human IGFBP-5, as described below.
Proteolysis of Native/Mutant IGFBP-5 by the IGFBP-5-specific Pro-
tease—Serum-free conditioned medium was obtained from human der-
mal fibroblasts (GM10 cells). These cells have been shown to secrete an
IGFBP-5-specific protease (28). Native or mutant IGFBP-5, 150 ng, was
incubated with 50 ml of conditioned medium in 60 mM Tris and 4 mM
CaCl2 with or without 200 ng of IGF-I in a total volume of 60 ml
overnight at 37 °C. The reaction mixture was then analyzed by immu-
noblotting as described below.
Immunoblotting—The samples were separated on SDS-polyacryl-
amide gel (8% for analysis of IGF-I receptor and 12.5% for analysis of
IGFBP-3 and IGFBP-5) and transferred onto a polyvinylidene difluo-
ride membrane, as described previously (24). For IGF-I receptor anal-
ysis, the membrane was probed with a 1:1000 dilution for PY99 or a
1:1000 dilution for C-20 and visualized by enhanced chemilumines-
cence, as described previously (29). IGFBP-3 and -5 were visualized by
an alkaline phosphatase method using a 1:1000 dilution of IGFBP-3
antibody or a 1:1000 dilution of IGFBP-5 antibody, as described previ-
ously (24). The results were quantified by scanning densitometry (Hoef-
fer Scientific, San Francisco, CA). The signal intensities were analyzed
using N.I.H. Image.
[3H]Thymidine Incorporation into DNA—To determine the effect of
IGFBP-3 and -5 and the mutants on [3H]thymidine incorporation into
DNA, increasing concentrations of mutant and wild type IGFBP-3
(25–700 ng/ml) or IGFBP-5 (250–7000 ng/ml) were added in the pres-
ence of 10 ng/ml of IGF-I. Quiescent, porcine aortic smooth muscle cells
(pSMC) were isolated as described previously (23, 30). They were plated
in 96-well plates at 5000 cells/cm2 in DMEM supplemented with 10%
fetal bovine serum. After 5 days the media were aspirated, and 0.2 ml
of fresh media containing 0.2% human platelet-poor plasma and test
concentrations of IGFBP-3 or -5 plus IGF-I and 0.5 mCi/well of [3H]thy-
midine (specific activity 33 Ci/mmol) was added. After 36 h, the amount
of [3H]thymidine incorporated into DNA was determined after extract-
ing the DNA as described previously (24).
Smooth Muscle Cell Migration—pSMC monolayers were grown to
confluency in 6-well plates in DMEM supplemented with 10% fetal
bovine serum. Confluent monolayers were wounded with a single-edged
razor blade as described previously (30). Test concentrations of IGF-I
and IGFBP-3 and -5 and their mutants were added in DMEM contain-
ing 0.2% fetal bovine serum. After 72 h, the number of cells migrating
across the line of wounding were counted, as described previously (30).
Cells were fixed and stained with methylene blue prior to counting. The
IGF Binding Site in IGFBP-3 and -5 18189
results are expressed as percent increase above a control containing
0.2% serum only.
Immunoprecipitation of the IGF-I Receptor—pSMC were grown to
near confluency on 60-mm plates. The cultures were washed three
times with serum-free DMEM and incubated with DMEM plus 0.01%
BSA for 24 h. The medium was changed to DMEM with 0.01% BSA
alone or this medium containing 1 mg/ml of each form of IGFBP. After
20 min at 37 °C, either vehicle or 100 ng/ml IGF-I was added for 10 min.
The medium was removed, and the cultures placed on ice and then
solubilized in 0.5 ml of lysis buffer (1% Nonidet P-40, 0.25% sodium
deoxycholate, 1 mM EGTA, 150 mM NaCl, 50 mM HEPES, pH 7.5, 100
mM sodium fluoride, 10 mM sodium pyrophosphate, 2 mM sodium van-
adate, 0.3 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin A, 1
mg/ml leupeptin). The insoluble material was removed by centrifugation
at 14,000 3 g for 10 min, and the supernatant was incubated with a
1:250 dilution of C-20 antibody overnight at 4 °C. The immune com-
plexes were precipitated by incubating with protein-A-Sepharose at
4 °C for 2 h, and then the immobilized protein A was sedimented by
centrifugation at 7000 3 g for 1 min and washed four times with the cell
lysis buffer. The proteins were resuspended in Laemmli sample buffer
with 0.1 M dithiothreitol. The immune complexes thus obtained were
analyzed by immunoblotting.
RESULTS
Synthesis of Mutant Forms of IGFBP-3 and -5 That Have
Reduced Affinity for IGF-I—Because the prior NMR study pre-
dicted that hydrophobic residues between Val49 and Leu75 of
IGFBP-5 formed the core of the IGF binding site, five of the
eight residues in that region that had been predicted to form
the binding pocket (i.e. Lys68, Pro69, Leu70, Leu73, and Leu74)
were mutated to Asn, Gln, Gln, Gln, and Gln, respectively (13).
Scatchard analysis, using the purified protein, showed that
mutant IGFBP-5 had a Kd of ;1000 nM, whereas native IG-
FBP-5 had a Kd of 0.56 nM. A mutant form of IGFBP-3 that had
substitutions for homologous residues was created by changing
Arg69, Pro70, Leu71, Leu74, and Leu75 to Ser, Ala, Ser, Gln, and
Gly, respectively. Native IGFBP-3 had a Kd of 0.69 nM, whereas
the mutant had a Kd of 930 nM. Thus, for both mutants the
affinity for IGF-I was reduced .1000-fold. When the ability of
increasing concentrations of mutant IGFBP-3 to bind 125I-IGF-
I was studied, a significant increase in binding was not de-
tected until 400 ng/ml was added. In contrast, a significant
increase in 125I-IGF-I binding was noted at 1.0 ng/ml when
native IGFBP-3 was used (Fig. 1A). Similar results were ob-
tained for mutant and wild type IGFBP-5, and concentrations
of either mutant below 100 ng showed no significant increase in
binding compared with controls that contained no IGFBP-5
(Fig. 1B).
The inability of both of the mutants to bind to 125I-IGF-I was
confirmed by Western ligand blotting. Neither 10 ng nor 40 ng
of mutant IGFBP-3 and IGFBP-5 showed detectable binding.
In contrast, both wild type proteins were easily visualized (Fig.
2A). When the same membrane was probed with antiserum
against IGFBP-3 and IGFBP-5, it was shown that comparable
amounts of native and mutant IGFBPs were adherent to the
membrane (Fig. 2B).
IGF-I Failed to Protect the Mutant Form of IGFBP-5 from
Proteolysis by the IGFBP-5 Protease—Native IGFBP-5 is
cleaved by a serine protease that is released by cultured human
fibroblasts (26). Previous studies have shown that incubation of
IGF-I with IGFBP-5 partially protects it from degradation by
this protease (20, 26). Because mutant IGFBP-5 is unable to
bind IGF-I, we determined whether it was protected from pro-
teolysis when incubated with the IGFBP-5-specific protease in
the presence of IGF-I. After an overnight incubation, native
IGFBP-5 was degraded and yielded a predominant 22-kDa
fragment (Fig. 3, lane 1). Inclusion of 100 ng of IGF-I with
native IGFBP-5 decreased proteolysis (Fig. 3, lane 2). When the
experiment was repeated three times, scanning densitometry
showed that the intensities of the intact native IGFBP-5 band
was reduced by 55 6 7% and in the presence of IGF-I by 24 6
13% (p , 0.05). In contrast, the mutant IGFBP-5 band inten-
sity was reduced by 48 6 8% without IGF-I and by 57 6 11%
with IGF-I (p, N.S.) (Fig. 3, lanes 5 and 6). Therefore, binding
of IGF-I to IGFBP-5 appears to be necessary for IGF-I to
protect IGFBP-5 from proteolysis by this protease.
Native IGFBP-5 Inhibited IGF-I-stimulated Phosphorylation
of IGF-I Receptor, whereas the Mutant IGFBP-5 Had Little
Effect—The addition of intact IGFBP-5 to the culture medium
has been shown to inhibit IGF-I-stimulated phosphorylation of
the IGF-I receptor (6, 24). Therefore, we determined whether
the mutant IGFBP-5 had any effect on IGF-I receptor phospho-
rylation. Incubation of pSMC with 100 ng/ml IGF-I resulted in
the stimulation of tyrosine phosphorylation of the IGF-I recep-
tor (Fig. 4). The addition of 1 mg/ml native IGFBP-5 to the
IGF-I-stimulated cultures prevented phosphorylation of IGF-I
receptor completely. On the other hand, the same amount of
the mutant IGFBP-5 did not alter the IGF-I receptor phospho-
rylation stimulation by IGF-I. The stimulation of phosphoryl-
ation of the IGF-I receptor by des-1–3-IGF-I that binds IG-
FBP-5 with very low affinity was not affected significantly by
the presence of native IGFBP-5 nor the mutant IGFBP-5 (data
not shown). The incubation of cells with either native or mu-
tant IGFBP-5 in the absence of IGF-I did not stimulate phos-
phorylation of IGF-I receptors (data not shown).
Migration—IGF-I is a potent simulator of cell migration (24,
30). This IGF-I action was also decreased by co-incubation of
pSMC with native IGFBP-5, but not with the mutant IGFBP-5.
50 ng/ml IGF-I-stimulated pSMC migration 121 6 33% over
control and the addition of 2.0 mg/ml of native IGFBP-5 de-
creased this response to a 58 6 16% increase over control
(Table I). In contrast, in the presence of 2.0 mg/ml mutant
IGFBP-5, migration was increased to 115 6 22% over control,
and this was not different than the cultures exposed to IGF-I
alone. Native IGFBP-3 also inhibited the IGF-I-induced migra-
tion of pSMC, but the IGFBP-3 mutant had little effect. 50
ng/ml IGF-I increased the migration of pSMC to 114 6 22%
over control, and 500 ng/ml of native IGFBP-3 decreased the
response to a 2 6 11% increase. When the IGFBP-3 mutant was
added with IGF-I, migration was increased 113 6 18% over
control (Table I).
[3H]Thymidine Incorporation—A molar excess of IGFBP-3 or
-5 can inhibit the ability of IGF-I to stimulate DNA synthesis
(24). Therefore, when molar ratios of 1.12:1, 2.25:1, and 9:1 of
wild type and mutant IGFBP-3 to IGF-I were added to quies-
cent pSMC cultures, the 4.3-fold increase in [3H]thymidine
incorporation that was stimulated by IGF-I was attenuated
84 6 8, 77 6 6, and 85 6 8%, respectively (p , 0.001 compared
with IGF-I alone, mean of three experiments) (Fig. 5A). In
contrast, the IGFBP-3 mutant had no effect on the response to
IGF-I. When IGFBP-5 was added using ratios of 2.9:1, 5.8:1,
and 23:1, the [3H]thymidine incorporation response to IGF-I
was inhibited by 88 6 5, 94 6 4, and 98 6 7%, respectively (p ,
0.001 compared with IGF-I alone) (Fig. 5B). The mutant IG-
FBP-5 had no effect.
DISCUSSION
These studies definitively demonstrate that a specific group
of hydrophobic amino acids within the N-terminal one-third of
IGFBP-3 and -5 is essential for IGF-I binding. Previous studies
using solution NMR spectroscopy had determined that a frag-
ment of IGFBP-5 containing this region of the protein folded in
such a way that these residues formed a hydrophobic patch
that was probably an important IGF-I binding site (6). Simi-
larly, other investigators had reported that N-terminal frag-
ments of IGFBP-2, -3, and -4 could bind to IGF-I (7–9, 25, 31,
32). Prior studies had to be conducted with IGFBP fragments,
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because when the intact proteins were used to make similar
determinations, an unacceptable level of aggregation obscured
the ability to make this determination by NMR spectroscopy.
However, the IGFBP fragments that have been analyzed pre-
viously have a significantly reduced affinity for IGF-I. There-
fore to determine if the putative solution structure of the bind-
ing epitope of the fragment would behave in a similar manner
within the whole protein, we chose to selectively alter five of
the eight residues of IGFBP-5 that were proposed to form this
hydrophobic patch.
The strategy to use these five residues rather than all eight
was dictated by the fact that the three other residues, at posi-
tions 49, 50, and 62, are separated from this pocket by several
residues. Additionally, making a smaller number of substitu-
tions would make it less likely that the effect of the substitu-
tions was due solely to an alteration in the tertiary structure of
the protein. This IGFBP-5 mutant had a .1000-fold reduction
in affinity for IGF-I. Although the solution structure of IG-
FBP-3 was not determined in the prior study (6), homologous
residues are present in IGFBP-3. Therefore we chose to mutate
these homologous residues to either neutral or nonhydrophobic
residues. The effect of these substitutions on the affinity of
IGFBP-3 for IGF-I was similar to that observed with IGFBP-5
(i.e. greater than 1000-fold reduction in affinity).
Although these substitutions would have destroyed the hy-
drophobic patch as predicted from the NMR model, we cannot
exclude the possibility that other changes in tertiary structure,
such as alteration of the disulfide bonding pattern or important
folding disruptions, occurred as a result of these substitutions.
Because five substitutions were present, this is certainly a
possibility. However, we favor the idea that this series of mu-
tations disrupted the hydrophobic patch and that this is the
principle reason that binding affinity is reduced. Several ob-
servations support this conclusion. First it is based on a ratio-
nal protein folding model proposed by Kalus et al. (6). Second,
no direct cysteine substitutions were performed, and therefore
FIG. 1. Binding of 125I-IGF-I to na-
tive and mutant forms of IGFBP.
0.25–100 ng of native (solid line) and mu-
tant (dashed line) forms of IGFBP-3 (A) or
IGFBP-5 (B) were incubated with 125I-
IGF-I, and the radioactivity that bound to
IGFBPs was precipitated using polyethyl-
ene glycol, as described under “Experi-
mental Procedures.” The radioactivity
precipitated in the absence of the IGFBPs
was subtracted as background, and the
data were expressed as a percentage of
the total isotope added that bound. The
result is the mean 6 S.D. (n 5 4) and is
the result of two independent experi-
ments. *, p , 0.01 compared with control
tubes that contained no binding protein.
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there is no reason a priori to believe that the disulfide bonding
pattern would be altered. Third, the identical substitutions in
IGFBP-3 resulted in a similar attenuation in affinity, suggest-
ing that if the effect were due solely to an alteration in tertiary
structure that the identical change would have to occur in
IGFBP-3, which has regions of sequence that are clearly dis-
tinct from IGFBP-5. Finally, the five substitutions are also in
close physical proximity with one another, making it less likely
that some other important structural determinant at a distant
site in the molecule was altered. For all of these reasons, we
believe that the model of Kalus et al. (6) is correct and is
validated by these data as presented.
These data do not exclude the possibility of important bind-
ing determinants in the C terminus of the IGFBPs. Other
laboratories have published data suggesting that fragments of
IGFBP-3 or -5 containing the only C-terminal region have some
affinity for IGF-I and -II (5, 21, 33). Other investigators have
noted that the C-terminal region of IGFBP-2 contains an IGF-I
binding site (20, 31, 34). Similarly, Bramani et al. (35) have
presented data suggesting that substitutions for residues 205
and 207 in IGFBP-5 results in a major loss of affinity of this
protein for IGF-I. The model of Kalus et al. (6) also proposed
that the C-terminal region, although not containing a distinct
high affinity site, could fold such that a critical C-terminal
region interacted cooperatively with the hydrophobic binding
pocket in the N terminus. This type of interaction has also been
proposed to occur in IGFBP-4 (32). Our data show only that the
N-terminal binding pocket is essential for high affinity binding
but do not help in determining the essentiality of the C-termi-
nal region binding domain. Similarly, they do not exclude its
possible importance in determining the binding affinity of the
whole protein.
Loss of binding resulted in major functional changes in IG-
FBP-3 and -5 actions. These proteins have been shown to be
potent inhibitors of several physiologic processes that are stim-
ulated by IGF-I. This was confirmed with the native forms of
IGFBP-3 and -5 showing that they could attenuate the IGF-I
response to cell migration and stimulation of [3H]thymidine
incorporation. Furthermore, we show that attenuation of IGF-I
receptor-stimulated autophosphorylation, the first step in
IGF-I signaling, is inhibited by wild type IGFBP-5, and the
FIG. 2. Ligand blot and immunoblot analysis of native and
mutant IGFBP-3 and -5. 10 or 40 ng of native and mutant IGFBP-3
and -5 were separated on 12.5% polyacrylamide gel and transferred
onto polyvinylidene difluoride membranes. The membrane was first
blotted with 125I-IGF-I (A) and then probed with anti-IGFBP-3 antibody
(B, lanes 1–4) or anti-IGFBP-5 antiserum (C, lanes 5–8), as described
under “Experimental Procedures.” Lane 1, 40 ng of native IGFBP-3;
lane 2, 10 ng of native IGFBP-3; lane 3, 40 ng of mutant IGFBP-3; lane
4, 10 ng of mutant IGFBP-3; lane 5, 40 ng of native IGFBP-5; lane 6, 10
ng of native IGFBP-5; lane 7, 40 ng of mutant IGFBP-5; lane 8, 10 ng of
mutant IGFBP-5. The upper arrow denotes the position of IGFBP-3,
and the lower arrow indicates the position of IGFBP-5. The figure is the
representative result of three experiments that gave similar results.
FIG. 3. Proteolysis of native and mutant IGFBP-5 by the IG-
FBP-5-specific protease. 150 ng of native (lanes 1–3) or mutant (lanes
4–6) IGFBP-5 was incubated for 14 h at 37 °C with fibroblast-condi-
tioned medium that contained IGFBP-5 protease activity (lanes 1, 2, 5,
and 6). IGF-I (200 ng) was added to the samples shown in lanes 2 and
6 and omitted from the samples shown in lanes 1 and 5. The samples
shown in lanes 3 and 4 were not exposed to the protease but were
incubated in buffer alone. The reaction mixtures were separated on
12.5% SDS-polyacrylamide gel electrophoresis and analyzed by immu-
noblotting using an antiserum against IGFBP-5. The upper arrow de-
notes the position of intact IGFBP-5, and the lower arrow indicates the
position of the major 22-kDa fragment. The figure is the representative
result of three experiments that gave similar results.
FIG. 4. The effect of native and mutant IGFBP-5 on IGF-I-
stimulated phosphorylation of the IGF receptor. A, subconfluent
pSMC were preincubated with 1 mg/ml of native IGFBP-5 or mutant
IGFBP-5 for 20 min before the addition of 100 ng/ml of IGF-I. After a
10-min incubation with IGF-I, cells were lysed, and the IGF receptor
was immunoprecipitated with anti-IGF receptor antibody. Precipitated
protein was analyzed by immunoblotting (6% polyacrylamide gel) using
an antibody against phosphotyrosine. B, when the membrane was blot-
ted with anti-IGF receptor antibody (1:1000 dilution), the result con-
firmed that the amount of IGF receptor that was detected was similar
for the different treatments. Lane 1, no treatment; lane 2, 100 ng/ml
IGF-I; lane 3, 100 ng/ml IGF-I and 1 mg/ml native IGFBP-5; lane 4, 100
ng/ml IGF-I; lane 5, 100 ng/ml IGF-I and 1 mg/ml mutant IGFBP-5.
Scanning densitometry values for the bands shown in A were: lane 1,
239; lane 2, 15,102; lane 3, 1663; lane 4, 16,060; and lane 5, 18,697. For
B they were: lane 1, 19,265; lane 2, 21,431; lane 3, 18,940; lane 4,
19,801; and lane 5, 21,251.
TABLE I
Smooth muscle cell migration
The data are expressed as percent increase over control cultures that
were exposed to 0.2% fetal bovine serum. *, p , 0.001 compared to
IGF-I alone.
Treatment % increaseover control
IGF-I 50 ng/ml 114 6 22
IGFBP-3 (wild type) 500 ng/ml 6 6 15
IGF-I 50 ng/ml 1 IGFBP-3 500 ng/ml 2 6 11*
IGFBP-3 (mutant) 500 ng/ml 19 6 3
IGF-I 500 ng/ml 1 IGFBP-3 (mutant) 500 ng/ml 113 6 18
IGF-I 50 ng/ml 121 6 33
IGF-I 50 ng/ml 1 IGFBP-5 2.0 mg/ml 58 6 16*
IGFBP-5 2.0 mg/ml 4 6 12
IGF-I 50 ng/ml 1 IGFBP-5 (mutant) 2.0 mg/ml 115 6 22
IGFBP-5 (mutant) 2.0 mg/ml 8 6 10
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mutant form of IGFBP-5 had no effect in attenuating IGF-I
signaling in this cell system. These data strongly suggest that
the major effect of IGFBP-3 and -5 on IGF-I-stimulated actions
is to prevent IGF-I receptor association. The data also show no
direct effects of concentrations of 500 ng/ml or less of IGFBP-3
and -5 on [3H]thymidine incorporation or cell migration in this
cell type. This stands in contrast to breast tumor cells and
other cancer cell lines, where IGFBP-3 has been shown to have
direct growth attenuating effects (35–38). These data suggest
that either nontransformed aortic smooth muscle cells are be-
having differently in response to IGFBP-3 and -5 compared
with these other cell types or that higher concentrations of
these proteins are required to demonstrate direct effects. These
mutants will be very useful in determining if IGFBP-3 and -5
have direct effects on cell types that secrete IGF-I, because they
will allow investigators to be able to exclude the possibility that
IGF-I produced in an autocrine or paracrine manner is modu-
lating the IGFBP actions.
In an additional experiment, we were able to show that
proteolytic cleavage of IGFBP-5 is partially inhibited by coin-
cubation with IGF-I. This inhibition did not occur when IGF-I
was incubated with the IGFBP-5 mutant. This result has two
important implications. First, it is likely that the mutant IG-
FBP-5 is folded correctly to expose its proteolytic cleavage site
because there was no difference in the amount of proteolytic
cleavage of the wild type compared with the IGFBP-5 mutant.
This further supports the conclusion that substitution for the
hydrophobic patch residues did not result in a major alteration
in conformation of the protein. Second, it has not been possible
in prior studies to determine if IGF-I was inhibiting proteolysis
by binding to the protease or by binding to IGFBP-5. These
data strongly suggest that binding to IGFBP-5 is required for
inhibition.
In summary, these studies demonstrate definitively that a
5-residue hydrophobic patch that has been postulated to be
part of the primary binding site in IGFBPs for IGF-I is neces-
sary for high affinity binding. Alteration of these hydrophobic
residues to nonhydrophobic residues results in a greater than
1000-fold reduction in affinity of IGFBP-3 and -5 for this li-
gand. This strongly suggests that IGFBP-3 and -5 will not bind
with high affinity without these residues. The minimum num-
ber of substitutions was not determined by this study, but the
findings suggest that if a fewer number of substitutions al-
lowed nearly equal reductions in affinity, it would be possible to
exclude that the tertiary structure has been altered to any
great extent.
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